Galantamine-ER for the treatment of mild-to-moderate Alzheimer's disease

被引:1
|
作者
Seltzer, Ben [1 ]
机构
[1] Harvard Univ, VA Boston Healthcare Syst, Geriatr Res Educ & Clin Ctr, Dept Neurol,Sch Med, Boston, MA 02130 USA
关键词
galantamine; cholinesterase inhibitors; Alzheimer's disease; CHOLINESTERASE INHIBITOR THERAPY; PLACEBO-CONTROLLED TRIAL; EXTENDED-RELEASE; DOUBLE-BLIND; NICOTINIC RECEPTORS; IMMEDIATE-RELEASE; DEMENTIA; ASSOCIATION; DONEPEZIL; EFFICACY;
D O I
暂无
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
An extended release form of the cholinesterase inhibitor (ChEI) drug galantamine (galantamine-ER) was developed, chiefly to increase adherence to medication regimes in patients with mild-to-moderate Alzheimer's disease (AD). Except for predicted differences in (C-max) and t(max), comparable doses of once daily galantamine-ER and regular, immediate release galantamine, (galantamine-IR), are pharmacologically equivalent. A 24-week randomized, double-blind, placebo-and active-controlled, multicenter phase III trial, which compared galantamine-IR, galantamine-ER and placebo in subjects with mild to moderate AD (mini-mental state examination [MMSE] score range, 10 to 24) showed that both formulations of galantamine were significantly better than placebo in terms of cognition, although not with regard to global change. There was no difference in drug-related adverse events between galantamine-ER and galantamine-IR. Since its release onto the market galantamine-ER has enjoyed wide popularity and a recent surveillance study suggests that it has the highest 1-year persistence rate of all the ChEIs.
引用
收藏
页码:1 / 6
页数:6
相关论文
共 50 条
  • [1] Memantine in the treatment of mild-to-moderate Alzheimer's disease
    Cosman, Kelly M.
    Boyle, Llsa L.
    Porsteinsson, Anton P.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (02) : 203 - 214
  • [2] Solanezumab for the treatment of mild-to-moderate Alzheimer's disease
    Imbimbo, Bruno P.
    Ottonello, Simone
    Frisardi, Vincenza
    Solfrizzi, Vincenzo
    Greco, Antonio
    Seripa, Davide
    Pilotto, Alberto
    Panza, Francesco
    [J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2012, 8 (02) : 135 - 149
  • [3] Galantamine has a broad spectrum of efficacy in mild-to-moderate Alzheimer's disease.
    Mintzer, JE
    Kershaw, P
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2002, 50 (04) : S23 - S23
  • [4] Gastrointestinal tolerability of once-daily galantamine in subjects with mild-to-moderate Alzheimer's disease
    Dunbar, F
    Zhu, Y
    Brashear, R
    [J]. INTERNATIONAL PSYCHOGERIATRICS, 2005, 17 : 312 - 312
  • [5] Switching, strategy with galantamine in the treatment of patients with mild to moderate Alzheimer's disease
    Hwang, T-Y.
    Ahn, I-S.
    Yun, J.
    Kim, S.
    Kim, D. K.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 172 - 172
  • [6] The Prediction of Response to Galantamine Treatment in Patients with Mild to Moderate Alzheimer's Disease
    Ohnishi, Takashi
    Sakiyama, Yojiro
    Okuri, Yuichi
    Kimura, Yuji
    Sugiyama, Nami
    Saito, Takayuki
    Takahashi, Masayoshi
    Kobayashi, Takumi
    [J]. CURRENT ALZHEIMER RESEARCH, 2014, 11 (02) : 110 - 118
  • [7] ANALYSIS OF THE EFFECT OF GALANTAMINE IN THE TREATMENT OF MILD TO MODERATE ALZHEIMER'S DISEASE (AD)
    Moruzzi, E.
    [J]. EUROPEAN PSYCHIATRY, 2012, 27
  • [8] Safety and effectiveness of galantamine for mild to moderate Alzheimer's disease
    Alvarez, F. J.
    Blesa, R.
    Ezpeleta, D.
    Romo, I.
    Garcia-Ribas, G.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 : 73 - 73
  • [9] Economic impact of galantamine in mild to moderate Alzheimer's disease
    Caro, J
    Migliaccio-Walle, K
    Ishak, KJ
    Getsios, D
    O'Brien, JA
    Papadopoulos, G
    [J]. ANNALS OF NEUROLOGY, 2001, 50 (03) : S79 - S79
  • [10] The safety of combined galantamine-memantine treatment in mild to moderate Alzheimer's disease
    Ramaswamy, K.
    Amatniek, J.
    Crivera, C.
    Rupnow, M.
    Zhu, Y.
    Hammond, G.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 : 68 - 68